PPM1D and myelodysplastic syndrome: We identified a significant association between prior exposure to platinum agents (cisplatin, carboplatin, and oxaliplatin) and PPM1D-mutated t-AML/t-MDS (odds ratio, 2.9; 95% CI, 1.2–7.1; p = 0.004; false discovery rate [FDR] = 0.056).